-
Healthcare Resource Utilization and Costs Among Bacillus Calmette-Guérin (BCG)-Experienced or Unresponsive Patients With Papillary-Only High-Risk Non–Muscle Invasive Bladder Cancer
Sep 9, 2025, 16:22 PM -
Investigation of the Impact of Hereditary Angioedema (HAE) on Health-Related Quality of Life: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Real-World Healthcare Resource Utilization and Related Costs Associated With Schizophrenia in the Brazilian Private Market
Sep 9, 2025, 16:22 PM -
The Role of Body Fat in the Regulation of Male Fertility
Sep 9, 2025, 16:22 PM -
Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective
Sep 9, 2025, 16:22 PM -
Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia
Sep 9, 2025, 16:22 PM -
Can Estimands Support Aligned Evidence Generation for EU HTA? Reflections on Their Role in Joint Clinical Assessments, PICO Alignment, and Beyond
Sep 9, 2025, 16:22 PM -
Budget Impact and Clinical Outcomes of Energy- and Nutrient-Dense Formulas in Pediatric Disease-Related Malnutrition: A Middle Eastern Analysis
Sep 9, 2025, 16:22 PM -
Paving the Path to Success for Joint Clinical Assessments: One Asset at a Time
Sep 9, 2025, 16:22 PM -
AI-Enabled Wearables for Fitness and Preventive Health
Sep 9, 2025, 16:22 PM -
Clinical and Economic Burden Imposed by Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Belgium
Sep 9, 2025, 16:22 PM -
Measuring the Disease Burden and Quality of Life From the Schizophrenia Caregivers’ Perspective
Sep 9, 2025, 16:22 PM -
Evaluating the Role of Patient-Reported Outcomes in Phase 4 Clinical Trials: Trends, Applications, and Implications for Postmarketing Surveillance
Sep 9, 2025, 16:22 PM -
Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis
Sep 9, 2025, 16:22 PM -
APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes
Sep 9, 2025, 16:22 PM -
Preliminary Observational Analysis of Digital Health Platform Associated With Medical Cost Changes in Employer Population
Sep 9, 2025, 16:22 PM -
Higher Mortality for Generalized Pustular Psoriasis Compared With Plaque Psoriasis Highlights the Need for Improved Treatments: Insights From a Meta-Analysis
Sep 9, 2025, 16:22 PM -
Navigating HTA Requirements: The Current Landscape of Alzheimer's Disease-Modifying Treatments
Sep 9, 2025, 16:22 PM -
Lifetime Secondary Healthcare Resource Utilization in Phenylketonuria From Birth to Adulthood in Sweden
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Iptacopan for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With C5 Inhibitor in the Brazilian Private Healthcare System
Sep 9, 2025, 16:22 PM
